Compare HQI & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HQI | IKT |
|---|---|---|
| Founded | 2002 | 2008 |
| Country | United States | United States |
| Employees | 75000 | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 232.1M | 220.5M |
| IPO Year | 2008 | 2020 |
| Metric | HQI | IKT |
|---|---|---|
| Price | $16.10 | $2.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $13.00 | $5.00 |
| AVG Volume (30 Days) | 23.6K | ★ 391.2K |
| Earning Date | 05-08-2026 | 03-26-2026 |
| Dividend Yield | ★ 2.08% | N/A |
| EPS Growth | ★ 73.08 | 57.76 |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $30,640,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.46 | N/A |
| P/E Ratio | $53.10 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.38 | $1.33 |
| 52 Week High | $19.01 | $2.61 |
| Indicator | HQI | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 55.82 | 58.17 |
| Support Level | $12.14 | $2.31 |
| Resistance Level | $17.78 | $2.53 |
| Average True Range (ATR) | 0.99 | 0.11 |
| MACD | -0.17 | -0.01 |
| Stochastic Oscillator | 58.10 | 63.24 |
HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The company's primary source of revenue is royalty fees based on the operation of its franchised offices.
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.